Comparative Pharmacology
Head-to-head clinical analysis: LIBRIUM versus XANAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRIUM versus XANAX.
LIBRIUM vs XANAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, potentiating GABAergic inhibition and increasing chloride ion conductance.
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
5-25 mg orally 3-4 times daily; or 50-100 mg intramuscularly or intravenously initially, then 25-50 mg 3-4 times daily as needed.
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
None Documented
None Documented
Terminal elimination half-life of chlordiazepoxide is 24-48 hours; active metabolite desmethyldiazepam has half-life of 36-200 hours; with repeated dosing, effective half-life extends due to accumulation of active metabolites.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates of chlordiazepoxide and demoxepam, <2% unchanged); approximately 60-70% of a dose appears in urine as metabolites, with 4-9% in feces via biliary elimination.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Category C
Category C
Benzodiazepine
Benzodiazepine